Brand Name(s):Victrelis
Indication:Chronic hepatitis-C genotype-1 infection, in combination with peginterferon alpha and ribavirin, in adult patients with compensated liver disease who are previously untreated or for whom previous therapy has failed.
Rationale:1,2,8
Considered:Jul-11
Review Date:Jan-20
Comments:
MHRA Update – November 2014
A European review identified the following baseline markers as predictive factors for morbidity requiring hospitalisation (eg, sepsis, worsening liver function) and mortality in cirrhotic patients treated with either boceprevir or telaprevir in combination with peginterferon alfa and ribavirin: low platelet count, hypoalbuminaemia, coagulopathy (for boceprevir only)
Boceprevir and telaprevir are not recommended for patients who have a low platelet count or hypoalbuminaemia before starting either of these medicines. Boceprevir is also not recommended for patients who have coagulopathy before starting it. If treatment is started, closely monitor for infection, worsening liver function, and anaemia, as described in the summary of product characteristics (see below).
http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON468289
NICE technology appraisal guidance 253
Boceprevir for the treatment of genotype 1 chronic hepatitis C
Guidance
Boceprevir in combination with peginterferon alfa and ribavirin is recommended as an option for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease:
who are previously untreated or in whom previous treatment has failed.
Issued: April 2012